Symbols

MRTX(Delisted)

Mirati Therapeutics·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MRTX

Mirati Therapeutics,Inc.

A clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer

Industry

Established Date

04/29/2013

Listing Date

07/15/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

587

Fiscal Year Ends

12-31

Website

mirati.com

Security Type

Common stock

Office address

3545 Cray Court, San Diego, California 92121

Business

Introduction

Mirati Therapeutics, Inc., incorporated under the laws of the State of Delaware on April 29, 2013, is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products. The Company focuses its development plans on drugs for the treatment of specific subpopulations of cancer patients to meet their needs. The company's pipeline consists of three product candidates: MGCD 265, MGCD 516 and mocetinostat. MGCD 265 and MGCD 516 are oral biotypes, multi-target kinase inhibitors currently in development for the treatment of patients with non-small cell lung cancer, head and neck squamous cell carcinoma and other solid tumors. MGCD 265 is currently in Phase 1/2 clinical development and MGCD 516 is in advanced preclinical development, and its first clinical phase is expected to begin in the first half of 2014. Mocetinostat is an oral biotype drug, a spectral selective histone deacetylase, an inhibitor that can treat first-line myelodysplastic syndromes. The company is planning to launch a Phase 3 clinical trial of mocetinostat by the end of 2014. In addition, it causes lymphoma or solid tumors in two clinical study patients whose tumors were found to have genetic alterations in preclinical models, and tumor cells showed greater sensitivity to mocetinostat.

Company Financials

EPS

MRTX has released its 2023 Q3 earnings. EPS was reported at -2.49, versus the expected -2.83, beating expectations. The chart below visualizes how MRTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MRTX has released its 2023 Q3 earnings report, with revenue of 16.40M, reflecting a YoY change of 201.97%, and net profit of -161.90M, showing a YoY change of 6.72%. The Sankey diagram below clearly presents MRTX's revenue sources and cost distribution.